Urology Times staff

“I think it's really important for us to understand how important this is not only for patients, but for ourselves, as we participate in this career and in teaching and advocating,” says Priya Padmanabhan, MD, MPH, FACS.

“Your vision is better, your instruments are better, and so we can do an excellent cancer operation while maintaining really good rates of continence and potency recovery,” says David Lee, MD.

“I think people can feel like they're all alone, or they have something that's uncommon, and it may not be,” says J. Quentin Clemens, MD, FACS, MSCI.

“I think it's important for urologists and physicians to have an open mind in regard to complementary approaches to the treatment of BPH-related LUTS in men,” says J. Curtis Nickel, MD, FRCSC.

“I think transgender patients come in particularly with a worry about experiencing mistreatment in a clinician's office, and particularly around genitourinary care,” says Gaines Blasdel.

“We definitely don't have a clear standard,” says Shawn Dason, MD, FRCSC.

“These findings are an internal validation that the disparities we're seeing are real,” says Padraic O’Malley, MD, MSc, FRCSC.

“Goal setting for the patient is important,” says Omar El Shahawy, MD, MPH, PhD.

“We call this a ‘disruptive innovation,’” says Leonard S. Marks, MD.

“The most notable finding is that more than half of all adult US women experience urinary incontinence,” says Heidi Wendell Brown, MD, MAS, FACOG.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Veda N. Giri, MD, highlights the role genetic testing has played in a new era of prostate cancer therapeutics.

“The current landscape of online materials about prostate cancer is generally pretty bleak,” says Stacy Loeb, MD, PhD, MSc.

“There are a few different approaches in perioperative medical chemotherapy or immunotherapy treatment, and it's unclear as to how we should consider all these different approaches,” says Shawn Dason, MD, FRCSC.

"A major innovation impacting urology and oncology is the therapeutic advances based on genetic information," says Veda N. Giri, MD.

“What really needs to be done to show that this works is to look prospectively,” says Amar U. Kishan, MD.

“Even though there [are] many therapies that one can do, it's not a sign of anything ominous for most men,” says Kevin T. McVary, MD, FACS.

We've never had an imaging agent like this before,” says Leonard S. Marks, MD.

“If you're looking at our results, in terms of the percent of authors who are female, the percent of first authors are female, or last authors who are female, we've seen growth in all 3 categories over the last 18 years,” said Megan Prunty, MD.

“I think that the most important thing to take home is that we all have implicit biases towards people who are underrepresented, whether it's women or minorities,” says Rena D. Malik, MD.

“The more you smoke, then the more prone you are to experience erectile dysfunction,” says Omar El Shahawy, MD, PhD.

“The important thing to know is that…we…aim to focus on the regions…that were not under the light of research education, in particular in the [genitourinary] space,” says Andrea Necchi, MD.

“The overall evidence in the global world literature is that saw palmetto can be effective,” says J. Curtis Nickel, MD, FRCSC.

“What we found was a signature that you can apply to patients to find out whether they're at high risk of these moderate or greater urinary side effects in the long term, and it did appear to depend on the type of radiation they were receiving,” says Amar U. Kishan, MD.

The patient received the treatment at Stanford Health Care, which had previously participated in the clinical trials examining the efficacy and safety of Exablate.

“I think there's a disconnect between the patients saying they're interested in these therapies, and the patients that actually go on to [receive] them,” says Jason Kim, MD.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Howard Goldman, MD, discusses the development of the midurethral sling as a treatment for stress urinary incontinence.

“What's interesting in Dr Strum's analysis of these trials is that he not only looked at the English literature, which many of us are familiar with, but he looked at the many studies done in countries that were published in the non-English literature and never found [their] way into any of our analyses,” says J. Curtis Nickel, MD, FRCSC.

"Introducing something that with a prefashioned sling, [something] we're able to utilize with the patient in an ideal situation just under some deep sedation and local, really opened this up the ability for many more women to be treated and allowed many more physicians to be trained and to utilize this technology," says Howard B. Goldman, MD, FACS.

“We’re going to review CHEK2-related management guidelines, hereditary cancer implications for males and their families…and the importance of cascade testing,” says Veda N. Giri, MD.

“Open your mind to being both [a mentee and mentor,] no matter where you are,” says Anne M. Suskind, MD, MS, FACS, FPMRS.